6-Hydroxy-5,6-dehydrosugiolCAS# 140923-35-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 140923-35-9 | SDF | Download SDF |
PubChem ID | 3009284 | Appearance | Powder |
Formula | C20H26O3 | M.Wt | 314.4 |
Type of Compound | Diterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | (4aR)-6,10-dihydroxy-1,1,4a-trimethyl-7-propan-2-yl-3,4-dihydro-2H-phenanthren-9-one | ||
SMILES | CC(C)C1=C(C=C2C(=C1)C(=O)C(=C3C2(CCCC3(C)C)C)O)O | ||
Standard InChIKey | XLUHSPYVUOVWRM-HXUWFJFHSA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. 6-Hydroxy-5,6-dehydrosugiol is a potent androgen receptor antagonist in prostate cancer cells, it has potential for use in chemoprevention and chemotherapy of prostate cancers. |
Targets | Androgen Receptor | Caspase | p53 | PARP | CDK |
6-Hydroxy-5,6-dehydrosugiol Dilution Calculator
6-Hydroxy-5,6-dehydrosugiol Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.1807 mL | 15.9033 mL | 31.8066 mL | 63.6132 mL | 79.5165 mL |
5 mM | 0.6361 mL | 3.1807 mL | 6.3613 mL | 12.7226 mL | 15.9033 mL |
10 mM | 0.3181 mL | 1.5903 mL | 3.1807 mL | 6.3613 mL | 7.9517 mL |
50 mM | 0.0636 mL | 0.3181 mL | 0.6361 mL | 1.2723 mL | 1.5903 mL |
100 mM | 0.0318 mL | 0.159 mL | 0.3181 mL | 0.6361 mL | 0.7952 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 4-Chloro-D-phenylalanine
Catalog No.:BCC2637
CAS No.:14091-08-8
- Aminopotentidine
Catalog No.:BCC6761
CAS No.:140873-26-3
- ICI 215,001 hydrochloride
Catalog No.:BCC5688
CAS No.:140850-02-8
- 1-Hydroxymethyl-beta-carboline glucoside
Catalog No.:BCN7026
CAS No.:1408311-12-5
- JNK-IN-7
Catalog No.:BCC1672
CAS No.:1408064-71-0
- PF 06465469
Catalog No.:BCC6268
CAS No.:1407966-77-1
- Scandine Nb-oxide
Catalog No.:BCN7504
CAS No.:140701-69-5
- 4-Aza-5androstan-1-ene- 3-one-17carboxylic acid
Catalog No.:BCC8693
CAS No.:140700-63-6
- 1-Deoxydihydroceramide-1-sulfonic acid
Catalog No.:BCC4964
CAS No.:1407-03-0
- Levatin
Catalog No.:BCN2531
CAS No.:140670-84-4
- Kadsurenin D
Catalog No.:BCN6603
CAS No.:140669-89-2
- 12-Hydroxyjasmonic acid
Catalog No.:BCN6224
CAS No.:140631-27-2
- (2R,3S)-Chlorpheg
Catalog No.:BCC6805
CAS No.:140924-23-8
- Benzo-18-crown-6 ether
Catalog No.:BCC8850
CAS No.:14098-24-9
- Benzo-15-crown 5-ether
Catalog No.:BCC8849
CAS No.:14098-44-3
- Nerylacetate
Catalog No.:BCN3802
CAS No.:141-12-8
- Ricinoleic acid
Catalog No.:BCC8248
CAS No.:141-22-0
- 2-Aminoethanol
Catalog No.:BCN1756
CAS No.:141-43-5
- Malonic acid
Catalog No.:BCN8534
CAS No.:141-82-2
- 2-Thiouracil
Catalog No.:BCC4752
CAS No.:141-90-2
- Frangulin B
Catalog No.:BCC8175
CAS No.:14101-04-3
- Gama-Tocotrienol
Catalog No.:BCN3720
CAS No.:14101-61-2
- PACOCF3
Catalog No.:BCC7074
CAS No.:141022-99-3
- 1-Hydroxy-2,3,4,7-tetramethoxyxanthone
Catalog No.:BCN6506
CAS No.:14103-09-4
A novel diterpene suppresses CWR22Rv1 tumor growth in vivo through antiproliferation and proapoptosis.[Pubmed:18701487]
Cancer Res. 2008 Aug 15;68(16):6634-42.
Androgen receptor (AR) is the main therapeutic target for treatment of metastatic prostate cancers (PCa). As recurrent tumors restore AR activity independent of hormones, new therapies that abolish AR activity have been sought to prevent or delay the emergence of ablation-resistant disease. Here, we report that a novel abietane diterpene, 6-Hydroxy-5,6-dehydrosugiol (HDHS), isolated from the stem bark of Cryptomeria japonica, was a potent AR antagonist in PCa cells. HDHS treatment of androgen-dependent LNCaP and androgen-responsive 22Rv1 cells induced apoptosis as shown by nucleosome release, activation of caspase-3 and caspase-7, and cleavage of poly(ADP-ribose) polymerase accompanied with concomitant up-regulation of tumor suppressor p53. HDHS also decreased the protein expression of cyclins (D1 and E), cyclin-dependent kinases (CDK2, CDK4, and CDK6), and retinoblastoma phosphorylation in PCa cells, which suggest cell cycle arrest in the G(1) phase. Oral administration of HDHS at 0.5 and 2.5 mg/kg once daily for 24 days to 22Rv1 PCa xenografted mice suppressed tumor growth by 22% and 39%, respectively, in association with decreased proliferation and increased apoptosis in tumor cells, which further correlated with increased levels of HDHS in plasma and tumors. Overall, our data suggest that HDHS has potential for use in chemoprevention and chemotherapy of PCa.